Skip to main content
IMS Events Main banner
Back
    21st International Myeloma Society Annual Meeting

    Oral Abstract Session

    Abstract Session 3

    Thursday, September 26, 2024
    5:30 PM – 6:30 PM East Coast USA Time
    Location: 101 A1-A2, Convention Center

    Presentations:

    • 5:30 PM – 5:42 PM East Coast USA Time
      OA – 46: Phase II clinical trial of minimal residual disease response-adapted deferral of transplantation in dysproteinemia (MILESTONE)

      Speaker: Susan Bal, MD – University of Alabama at Birmingham

    • 5:42 PM – 5:54 PM East Coast USA Time
      OA – 49: Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ)

      Speaker: Meletios A. Dimopoulos, MD – National and Kapodistrian University of Athens

    • 5:54 PM – 6:06 PM East Coast USA Time
      OA – 51: Efficacy of Dara-RVD induction therapy in newly diagnosed myeloma (NDMM) patients ≥65 years of age

      Speaker: Nisha S. Joseph, MD – Winship Cancer Institute, Emory University

    • 6:06 PM – 6:18 PM East Coast USA Time
      OA – 52: Isatuximab plus lenalidomide and dexamethasone with bortezomib versus isatuximab plus lenalidomide and dexamethasone in newly diagnosed transplant ineligible Multiple Myeloma: The BENEFIT study.

      Speaker: Xavier P. Leleu, MD, PhD (he/him/his) – Hospital La Mileterie, Poitiers, France

    • 6:18 PM – 6:30 PM East Coast USA Time
      OA – 55: Iberdomide, daratumumab, and dexamethasone (IberDd) in transplant-ineligible (TNE) newly diagnosed multiple myeloma (NDMM): results from the CC-220-MM-001 trial

      Speaker: Paula Rodriguez-Otero, MD PhD (she/her/hers) – Clinica Universidad de Navarra